Moody's gives Boston Scientific notes A3

Moody's Investors Service said it assigned an A3 rating to Boston Scientific Corp.'s new $600 million senior unsecured note offering.

The outlook is stable.

The A3 long-term debt rating reflects Moody's expectations that the company will continue to generate solid free cash flow despite a more crowded and volatile drug eluting stent market and will maintain ratios of operating cash flow to adjusted debt and free cash flow to adjusted debt of about 50% and 45%, respectively, through 2006, assuming any settlement of outstanding litigation with Johnson & Johnson is no greater than $750 million.

The agency added the ratings also reflect high concentration risk in one product and potential cash flow volatility associated with higher competition, technological obsolescence and regulatory issues.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.